Vertex receives CHMP positive opinion for Kaftrio in children with cystic fibrosis
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read Moreby Lucy Parsons | Nov 15, 2021 | News | 0
Those eligible will have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene
Read Moreby Selina McKee | May 20, 2021 | News | 0
If approved, up to 2,000 children with CF would be eligible for treatment with the drug
Read Moreby Lucy Parsons | May 11, 2021 | News | 0
Extension of indication expands access to drug for additional cystic fibrosis patients in Great Britain
Read Moreby Lucy Parsons | Apr 29, 2021 | News | 0
Extension means the ‘majority’ of people aged 12 years and older with CF in Europe can now access therapy
Read Moreby Selina McKee | Aug 24, 2020 | News | 0
Clearance was based on two global Phase III studies showing statistically significant improvements in lung function
Read Moreby Selina McKee | Jul 23, 2020 | News | 0
The letter of intent should secure access to the combination for people with cystic fibrosis upon its regulatory approval
Read Moreby Selina McKee | Jul 1, 2020 | News | 0
CF patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the EC
Read Moreby Selina McKee | Jun 29, 2020 | News | 0
The recommendations include a conditional approval for Gilead’s Veklury (remdesivir) for COVID-19
Read More





PharmaTimes Media Ltd.
44 Maiden Lane
Covent Garden
London
WC2E 7LN
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
